Skip to main content
padlock icon - secure page this page is secure

Blood Compatibility of Polyamidoamine Dendrimers and Erythrocyte Protection

Buy Article:

$106.34 + tax (Refund Policy)

Dendrimers are global macromolecules with promising biomedical application. In order to investigate their blood compatibility, different generations of polyamidoamine (PAMAM) dendrimers terminated with different types of surface functional groups were incubated with red blood cells (RBC) for time course of haemolysis assay and RBC morphology observation. Cationic PAMAM dendrimers demonstrated obvious generation, concentration and time dependent haemolysis while anionic and neutral PAMAM dendrimers were much less hemolytic. The surface amino groups and the polymeric structure of cationic PAMAM dendrimers played pivotal roles in haemolysis induction; meanwhile the basic pH of cationic PAMAM solutions was an inneglectable factor. Due to the presence of plasma proteins in abundance, whole blood was found tolerable to haemolysis induced by dendrimers, possibly through complex formation of plasma proteins with cationic PAMAM dendrimers. It was deduced that poly-carboxylic acids may have the similar effect as that of plasma proteins. So by means of pH adjustment to the physical 7.4, reduction of administration dose and the combined use of plasma protein (or other protective additives such as negatively charged molecules), the blood compatibility and even biocompatibility of cationic dendrimers may be enhanced to “safe” level.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Keywords: BLOOD COMPATIBILITY; CYTOTOXICITY; HAEMOLYSIS; PAMAM DENDRIMERS; RBC AGGREGATION

Document Type: Research Article

Publication date: February 1, 2010

More about this publication?
  • Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more